Sera Prognostics Inc (SERA)
Sera Prognostics, Inc. is a healthcare company focused on women’s health. It develops and commercializes blood-based biomarker tests and related predictive analytics products and services in the United States. Its main product is the PreTRM test, a non-invasive blood test used during weeks 18 to 20 of pregnancy for women carrying a single fetus. The company also has a development pipeline that includes tests and analytics for pregnancy-related conditions such as time-to-birth, preeclampsia, and fetal growth restriction. Sera Prognostics was incorporated in 2008 and is based in Salt Lake City, Utah.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SERA
|
$2.36
|
10.6% Upside
|
Fair
|
$5.50
|
158.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 11, 2026
|
1.4x
|
1,194.8x
|
84.027 M
|
6.376 M
|
3.5%
|
70.2%
|
-4.6
|
84.7%
|
